Drug Type Small molecule drug |
Synonyms NRG |
Target |
Action antagonists |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC15H12O5 |
InChIKeyFTVWIRXFELQLPI-ZDUSSCGKSA-N |
CAS Registry480-41-1 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatitis C, Chronic | Phase 1 | United States | 01 Jun 2009 | |
| Osteoporosis, Postmenopausal | Preclinical | India | 16 Oct 2025 | |
| Pseudorabies | Preclinical | China | 01 Jul 2025 | |
| Chronic constipation | Preclinical | China | 24 Jun 2025 | |
| Alzheimer Disease | Preclinical | Iran | 23 May 2025 | |
| Pseudomonas aeruginosa infection | Preclinical | China | 09 Apr 2025 | |
| Breast Cancer | Preclinical | United States | 03 Apr 2025 | |
| Staphylococcus Aureus Infections | Preclinical | Brazil | 26 Mar 2025 |





